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Introduction: Screening all older adults for Alzheimer’s disease and related dementias (ADRD) 
in primary care may not be acceptable or feasible. The goal of this study was to identify factors 
that could optimize screening in primary care and enhance its feasibility.
Methods: This is a cross-sectional study in rural, suburban, and urban primary care practices in 
Indiana. A total of 1,723 patients $65 years of age were screened for ADRD using the Memory 
Impairment Screen. Logistic regression was used to identify patient-specific factors associated 
with screening positive for ADRD.
Results: The positive screening rate was 4.9%. Rates varied significantly across the three study 
sites. The rural site had the lowest rate (2.8%), which was significantly lower than the rates at 
the suburban (5.6%) and urban (6.6%) sites (P,0.01). Patient age, sex, and education were 
significantly (P,0.05) associated with screening positive for ADRD.
Conclusion: Targeted screening of patients at risk for ADRD may represent a more optimal 
and feasible screening alternative to population screening.
Keywords: dementia screening, Alzheimer’s disease screening, primary care
Background
The National Academy of Sciences, the National Plan to Address Alzheimer’s Disease, 
and the Affordable Care Act, through the Medicare Annual Wellness Visit, all identify 
early detection of Alzheimer’s disease and related dementias (ADRD) as a core aim for 
improving the care quality for older adults.1–3 ADRD are debilitating conditions that 
impair memory, thought processes, and functioning, primarily among older adults.4 
Nevertheless, the USA Preventive Services Task Force currently does not recommend 
ADRD screening due to the lack of evidence about the risks and benefits of early 
detection as well as lack of effective treatments.5
Given the uncertainty regarding routine, population screening, targeted screening 
of people at risk for ADRD may represent an alternative to traditional population 
screening.6,7 Patient characteristics, such as education and comorbidity burden,8,9 as 
well as lifestyle factors,10 have been shown to correlate with cognitive impairment 
screening results. For example, some research has shown that patients who score 
worse on cognitive assessment are more likely to be female, African-American, and 
have less years of formal education.11–13 However, sample sizes of previous studies 
have been relatively small with limited generalizability.
The aim of this study is to report the rate of positive ADRD screening tests in a 
large and diverse cohort of older adults from urban, suburban, and rural sites and to 
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identify factors associated with screening positive. Results 
from this study are intended to help determine the optimal 
setting or population for targeted ADRD screening efforts.
Methods
Participants
Participants for this study were enrolled in the Indiana 
University Cognitive Health Outcomes Investigation of the 
Comparative Effectiveness of Dementia Screening (CHOICE) 
trial. CHOICE is an ongoing, multisite randomized controlled 
trial to test the risks and benefits of screening for ADRD in 
primary care.14 It includes 4,005 primary care patients aged 
65 years or older who receive their primary care from one of 
the three health care systems in central Indiana. The cohort 
of patients for these analyses includes 1,723 individuals who 
are enrolled in the CHOICE trial and were randomized to 
be screened for ADRD. The sites include Eskenazi Health, 
Indiana University Health (IUH) Indianapolis and IUH Arnett. 
Eskenazi Health is an urban, safety net health care system with 
eleven federally qualified health care centers staffed by faculty 
and residents of Indiana University School of Medicine. IUH 
Indianapolis includes five suburban primary care practices in 
Marion County, IN. The third site, IUH Arnett, is a regional 
health care center in rural Indiana, which is part of the IUH 
system and serves patients in the cities of Lafayette and 
West Lafayette, and the surrounding areas in Tippecanoe 
County, IN. Patients from eight primary care practices in the 
Arnett catchment area were recruited for the CHOICE trial. 
The CHOICE trial was approved by the institutional review 
boards (IRBs) of Indiana University–Purdue University in 
Indianapolis and IUH Arnett Hospital and is registered with 
ClinicalTrials.gov (NCT01699503). Participants who were 
enrolled in-person provided written informed consent to 
participate in the study. Participants who were enrolled by tele-
phone provided a verbal consent, as per our waiver of written 
informed consent from the IRBs at Indiana University–Purdue 
University in Indianapolis and IUH Arnett Hospital.
Patients were eligible if they were 65 years or older, had 
at least one visit to their primary care physician in the past 
12 months, did not already have a previous or preexisting 
diagnosis of ADRD or mild cognitive impairment, and had 
the ability to communicate in English. Patients were excluded 
from the study if they were a permanent resident of a nurs-
ing facility, had a serious mental illness, or had been given 
a prescription for a cholinesterase inhibitor or memantine. 
Patients were randomized equally into two arms (screening 
or no screening).14
Patients randomized to the screening arm were screened 
with the Memory Impairment Screen (MIS) at baseline 
either in-person or by phone.15,16 The MIS required 4 minutes 
to administer and included a non-cued and cued recall. 
Participants were presented with four target words and 
associated cues. After 2–3 minutes of unrelated tasks, par-
ticipants were asked to recall the four words. For words not 
identified by free recall, the interviewer provided the cues 
for those words. Scoring the MIS consisted of multiply-
ing the number of free recall items by two and adding the 
number of cued recall items, resulting in a possible score 
range of 0–8. Using a cutoff score of 4 or less, the MIS has 
been shown to have 86% sensitivity and 97% specificity for 
identifying memory impairment.15 The telephone version 
of the MIS, the MIS-T, displayed similar characteristics 
with a sensitivity of 78% and a specificity of 93%.16 All 
patients who scored a 4 or less on the MIS were referred for 
a voluntary diagnostic assessment. Results comparing the 
positive screening tests with diagnostic assessment data will 
be presented in an upcoming paper. Patient demographic 
variables were assessed during the baseline interview. The 
presence of nine common geriatric chronic conditions and 
the Charlson Comorbidity Index score17 were obtained 
from the Indiana Network for Patient Care (INPC), which 
is a regional health information infrastructure that includes 
a network of over 80 hospitals and their patient medical 
record systems. The INPC research database contains over 
17.2 million individual patients, 4.6 billion clinical observa-
tions, and 165 million text reports, with 68% of the Indiana 
population captured in 2014.18
statistical analyses
We used Fisher’s exact test to compare categorical demo-
graphic variables across the three different study sites. 
We used Kruskal–Wallis test for differences in the Charlson 
Comorbidity Index score, which has a skewed distribu-
tion. We used Fisher’s exact test to compare differences 
in the percentage of patients screening positive by socio-
demographic and comorbidity factors. When items with 
more than two categories were found to be significant, we 
performed pairwise comparisons to determine group differ-
ences. We used the step-down Bonferroni method to adjust 
for multiple pairwise comparisons within each variable. We 
used a logistic regression model to simultaneously examine 
the association of demographic factors and study site with 
positive ADRD screening tests. All analyses were conducted 
using SAS v9.4 (Cary, NC, USA).
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Results
Patient demographic and clinical 
characteristics by study site
In the CHOICE trial, 4,005 patients were enrolled, and 
2,008 were randomized to the screening group. To ensure 
complete and accurate data, 1,723 were included in the 
analysis. To meet the enrollment targets, 7,317 patients 
were approached, and the exclusion and refusal rate for the 
study was 43%.
Demographic and comorbidity comparisons by study site 
are presented in Table 1. There are significant differences 
in sociodemographics across the three sites. Patients at the 
urban site (Eskenazi Health) were significantly younger and 
had fewer years of education than patients at the suburban 
and rural sites (IUH Indianapolis and IUH Arnett, respec-
tively; both P,0.001). Race also differed significantly, 
with almost no African-American patients at the rural site 
(P,0.001). Specifically, 27% of patients at suburban site 
were African-American, while the majority of patients (60%) 
at the urban site were African-American. Although sex dif-
fered by site, the majority of patients were female at all three 
sites (63%–72%). Patients at the rural site had significantly 
fewer chronic comorbidities (P,0.001), which resulted in 
significantly lower Charlson Comorbidity Index scores as 
compared to patients at suburban and urban sites (2.0 versus 
3.4 and 3.8, respectively; P,0.001; Table 1). Pairwise com-
parisons for race, age, education, sex, and comorbidity, by 
site, did not differ from the overall comparisons presented 
in Table 1 (results not shown).
Positive screening rate by study site and 
patient sociodemographics
Positive screening rates by sociodemographic characteristics 
and comorbid conditions are presented in Table 2. Overall, 
the positive screening rate was 4.9%; however, the rates 
varied significantly (P=0.003) across the three study sites. 
The rural site had the lowest rate of patients who screened 
positive (2.8%), which was significantly lower than the rates 
at the suburban and urban sites (5.6% [P=0.007] and 6.6% 
[P=0.004], respectively). Patients aged 80 years and older 
as well were significantly more likely to screen positive 
than patients aged 65–69 years (P=0.027) and patients aged 
Table 1 Demographic and clinical characteristics by site
Variable Urban sitea 
(N=725)
Suburban siteb 
(N=345)
Rural sitec 
(N=653)
P-value
Age in years, % (n)    ,0.001
65–69 51.3 (372) 26.4 (91) 18.2 (119)  
70–79 39.3 (285) 49.0 (169) 53.3 (348)
$80 9.4 (68) 24.6 (85) 28.5 (186)  
sex, % (n)    0.002
Male 27.9 (202) 37.4 (129) 34.6 (225)  
Female 72.1 (523) 62.6 (216) 65.4 (428)  
race, % (n)    ,0.001
African-American 59.8 (432) 27.0 (93) 0.2 (1)  
White 38.0 (275) 71.3 (246) 98.5 (643)  
Other 2.2 (16) 1.7 (6) 1.4 (9)
education, % (n)    ,0.001
0–8 years 10.5 (75) 0.6 (2) 0.6 (4)  
9–11 years 31.5 (226) 5.2 (18) 5.8 (38)
high school or high school equivalent 29.7 (213) 32.6 (112) 37.7 (246)  
some college, college degree, or postgraduation 28.3 (203) 61.5 (211) 55.5 (364)  
Comorbidities, % (n)
hypertension 91.6 (662) 89.6 (309) 75.5 (493) ,0.001
Diabetes 52.8 (382) 48.1 (166) 30.2 (197) ,0.001
Myocardial infarction 15.1 (109) 13.6 (47) 8.6 (56) 0.001
Congestive heart failure 24.2 (175) 20.3 (70) 9.5 (62) ,0.001
COPD 55.5 (401) 46.1 (159) 22.5 (147) ,0.001
liver disease 6.9 (50) 9.6 (33) 4.0 (26) 0.002
history of cancer 14.5 (105) 23.5 (81) 10.6 (69) ,0.001
Depression 38.4 (278) 31.3 (108) 17.0 (111) ,0.001
Charlson Comorbidity Index score, mean (sD) 3.4 (3.0) 3.8 (3.3) 1.9 (2.3) ,0.001
Notes: aeskenazi health. bIndiana University health, Indianapolis. cIndiana University health, Arnett.
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70–79 years (P=0.027). African-American patients were sig-
nificantly more likely to screen positive for memory impair-
ment than white patients (P=0.002). There were significant 
differences (P,0.001) in the rate of positive screening by 
education level. Specifically, those patients who had some 
college, a college degree, or postgraduate education had sig-
nificantly lower rates than those with 0–8 years of education 
(P=0.016) and those with 9–11 years of education (P=0.001). 
Patients with a history of COPD were also significantly more 
likely to screen positive compared to patients without COPD 
(P=0.016; Table 2).
logistic regression analysis to identify 
factors associated with positive screening
Logistic regression analysis was conducted to identify factors 
associated with odds of screening positive for memory 
impairment (Table 3). Younger age was associated with 
reduced odds of screening positive (65–69 years: OR 0.32, 
95% CI 0.17, 0.60; 70–79 years: OR 0.40, 95% CI 0.23, 
0.69; both P,0.001). However, males and those with less 
education had increased odds of screening positive (both 
P,0.05). Odds of a positive screening test increased incre-
mentally with decreasing years of education such that those 
with 0–8 years of education had an OR of 3.16 compared 
to those with at least a high school degree or more years of 
education (OR 2.05; Table 3).
Discussion
This study aimed at exploring the rate of positive screening 
tests for memory impairment in a large and diverse cohort of 
older primary care patients from urban, suburban, and rural 
sites and at identifying factors associated with screening 
positive for ADRD in primary care. The rates of positive 
screening were greater in patients aged $80 years, males, 
African-Americans, and those with less education.
Our study found a wide variation in positive screening 
rates, ranging from 2.8% to 6.6%, across the three sites, with 
an overall positive screening rate of 4.9%. Our overall rate 
was lower than other ADRD screening studies conducted in 
primary care.19–22 When explored by site, the urban site had 
the highest rate of positive screening at 6.6%, which was 
lower than the rate reported in a previous screening study 
conducted at the same urban site for this analysis 5 years 
earlier, which was 13%.12 The lower rates could be reflective 
of our choice of screening instrument, changing incidence 
rates,23 or our population which was generally younger with 
more years of formal education, the last two being associated 
with decreased likelihood of ADRD.8,24,25 Alternatively, the 
unexpectedly low positive screening rate could be a reflection 
of incidence rates, compared to prevalence rates, given the 
number of ADRD-related studies our group has conducted in 
these settings over the past two decades.8,12,19,26–28 Moreover, 
recent epidemiological studies have shown a reduction in 
the incidence rates of dementia,23,29,30 and an analysis of the 
Framingham study has shown a greater decline in younger 
age groups.31 Changing patient factors, including increased 
education and lifetime cognitive stimulation,32 decreased 
vascular risk factors,33 or tobacco control,34 may contribute 
to the decline. Also, others have suggested that the decline 
is greater in different age groups, especially in younger 
age groups. Additionally, the screening instrument used in 
this study or the lack of adjustment of the cutoff score by 
age, sex, and education may have contributed to the low 
rates. Other tools created for and tested in primary care that 
Table 2 Positive screening rate by site and demographics
Variable Patients who 
screened 
positive
P-value
Overall rate of positive ADrD 
screening tests, % (n)
4.9 (83)
study site, % (n)  0.003
Urbana 6.6 (46)
suburbanb 5.6 (19)
ruralc 2.8 (18)
Age in years, % (n)  0.015
65–69 4.0 (23)
70–79 4.2 (33)
$80 8.2 (27)
sex, % (n)  0.092
Male 6.2 (34)
Female 4.3 (49)
race, % (n)  0.002
African-American 7.9 (40)
White 3.6 (42)
Other 3.3 (1)
education, % (n)  ,0.001
0–8 years 10.3 (8)
9–11 years 8.4 (23)
high school or high school equivalent 5.5 (31)
some college, college degree, or 
postgraduation
2.7 (21)
Comorbidities, % (n)
hypertension 5.1 (73) 0.530
Diabetes 5.7 (41) 0.256
Myocardial infarction 6.7 (14) 0.228
Congestive heart failure 7.0 (21) 0.076
COPD 6.5 (45) 0.016
liver disease 5.6 (6) 0.646
history of cancer 5.6 (14) 0.527
Depression 5.0 (24) 1.000
Notes: aeskenazi health. bIndiana University health, Indianapolis. cIndiana University 
health, Arnett.
Abbreviation: ADrD, Alzheimer’s disease and related dementias.
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are more sensitive to factors such as education or age, for 
example, the Mini-Cog and the General Practitioner assess-
ment of Cognition, have been found to be viable ADRD 
screening tools that are recommended for use in primary 
care settings.3,22,35–41 We selected the MIS because of its 
psychometric properties, feasibility of use in the primary 
care setting, and its administration over telephone. Future 
studies of population-level ADRD screening may want 
to consider using other instruments, such as the Montreal 
Cognitive Assessment, which has recently been validated 
in a national sample.24
Of the three sites, the rural site had the lowest positive 
screening rate, despite the fact that a higher proportion of 
participants was $80 years of age. However, this site was 
screened primarily by phone, and its population was also 
highly educated (93.2% had at least a high school education) 
and had less medical comorbidities, both of which are known 
to be related to the risk of ADRD.25–27,33,34 Moreover, this 
group had a higher socioeconomic status (data not shown), 
which can positively contribute to reduced comorbidities.35
We found that older age and decreasing years of educa-
tion were significantly associated with increased likelihood 
of a positive screening, which is consistent with the current 
literature.24–27,42 However, we found that males were more 
likely to screen positive than females, which has been 
inconsistent with the current literature of screening in primary 
care.43–45
When implementing a screening program in primary 
care, the goal is to maximize benefits and minimize harms of 
detection. For ADRD screening, minimizing the harms may 
be best achieved by using an instrument with high specificity 
to minimize false-positive screening as well as targeted 
screening.3,46 To optimize the yield of ADRD screening, 
future programs may target primary care patients who are 
older, have less education, and suffer from comorbidities.
Limitations
There are some limitations to the study. First, the refusal 
rate for the study was high (43%). Patients who refused to 
participate in the study may be at higher risk for ADRD; 
therefore, our overall rate of 4.9% of patients who screened 
positive may be an underestimate of the true rate in our 
population. Also, patients assessed by phone were from the 
rural study site (IUH Arnett); therefore, we cannot determine 
if the differences were due to the mode of administration of 
the screening test or the demographic differences observed 
in that population. Another limitation is that we did not use 
age- or education-specific cutoff points for the MIS or MIS-T, 
and the findings for site differences could be due to age, sex, 
and education differences among the sites.
Table 3 regression results for screening positive for ADrD
Variable Univariate results Multivariate results
OR (95% CI) P-value OR (95% CI) P-value
study site 0.006 0.259
rurala 0.40 (0.23, 0.70) 0.001 0.62 (0.29, 1.36) 0.234
suburbanb 0.84 (0.48, 1.46) 0.536 1.12 (0.58, 2.19) 0.735
Urban (reference)c 1.00 1.00
Age in years 0.012 0.001
65–69 0.48 (0.27, 0.84) 0.011 0.32 (0.17, 0.60) ,0.001
70–79 0.50 (0.29, 0.84) 0.009 0.40 (0.23, 0.69) 0.001
$80 (reference) 1.00 1.00
sex
Female 0.68 (0.43, 1.06) 0.087 0.57 (0.36, 0.91) 0.019
race 0.001 0.126
African-American 2.28 (1.46, 3.57) ,0.001 1.80 (0.90, 3.60) 0.128
Other 0.91 (0.12, 6.84) 0.927 1.10 (0.14, 8.54) 0.924
White (reference) 1.00 1.00
education ,0.001 0.022
0–8 years 4.07 (1.74, 9.52) 0.001 3.16 (1.25, 8.02) 0.016
9–11 years 3.26 (1.77, 5.99) ,0.001 2.48 (1.26, 4.90) 0.009
high school or high school equivalent 2.08 (1.18, 3.65) 0.011 2.05 (1.15, 3.65) 0.015
some college, college degree, or postgraduation (reference) 1.00 1.00
Comorbidities
COPD 1.76 (1.13, 2.74) 0.013 1.43 (0.89, 2.28) 0.139
Notes: aIndiana University health, Arnett. bIndiana University health, Indianapolis. ceskenazi health.
Abbreviation: ADrD, Alzheimer’s disease and related dementias.
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Conclusion
The low rates of positive screening and the regional variation 
observed in this study suggest that more targeted programs 
to identify patients at risk for ADRD may represent a better 
alternative to population screening. Such targeted screening 
strategies could use patient characteristics, including those 
identified in the present study (ie, older age, less education, 
and non-white), to identify the best screening tool and 
to select potential patients who may benefit most from 
screening. These strategies will likely minimize any harm 
associated with screening as well as maximize the benefit of 
detecting early cases.
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